NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 57 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Subsidiary Innoxel Receives USFDA EIR for Vadodara Injectable Facility
Bharat Parenterals' subsidiary, Innoxel Lifesciences, received an Establishment Inspection Report (EIR) from the USFDA on November 4, 2026. This closes the unannounced Pre-Approval Inspection (PAI) conducted between April 13 and April 20, 2026, for a general injectable product at its Vadodara facility. The USFDA confirmed the plant is ready for commercial operations, marking the second EIR received by this facility alongside an EU-GMP certificate across 4 lines. This regulatory clearance follows Innoxel's first commercial supply launch to the US market in October 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe USFDA has officially closed the April 2026 unannounced PAI and cleared the Vadodara injectable facility for commercial operations.
ஏன் இது முக்கியம்De-risks regulated-market commercialization for Innoxel, opening export channels for complex generic injectables into the US CDMO market.
EIR Issue Date: நவம்பர் 4, 2026Inspection Period: ஏப்ரல் 13, 2026 to ஏப்ரல் 20, 2026EU-GMP Manufacturing Lines Covered: 4 linesTTM Net Profit: Rs -30 Cr
📅 குறுகிய காலம்Positive sentiment driver for the stock as regulatory overhang regarding the April 2026 unannounced USFDA inspection is successfully resolved.
📈 நீண்ட காலம்Strengthens Innoxel's positioning as a CDMO partner for regulated markets (US and EU), potentially enhancing export revenue and margin profile over coming quarters.
⚠ அபாய எச்சரிக்கைகள்
Company is currently loss-making at TTM level (TTM PAT Rs -30 Cr)
Commercial uptake and volume off-take depend on US sponsor partner performance
👀 கவனிக்க வேண்டியவை
Track the ramp-up of US injectable contract manufacturing supplies and watch upcoming quarterly financial results for evidence of operational turnaround from recent TTM net losses (-Rs 30 Cr).
Bharat Parenterals Q2FY27 Earnings Call: Group Turns Profitable With PAT at ₹11.8 Cr
Bharat Parenterals reported a sharp commercial inflection in Q2FY27, with consolidated revenue surging 110% YoY to ₹136.3 crore and EBITDA reaching ₹23.6 crore (17.3% margin). The group swung from a net loss of ₹8.6 crore in Q2 last year to a consolidated PAT of ₹11.8 crore, driven by high-margin contributions from its subsidiary Innoxel Life Sciences. Innoxel achieved an EBITDA margin of 33% (EBITDA of ₹14.6 crore) and commenced its first commercial CMO exports to the US in late October 2026. Standalone operations also recovered with ₹78.6 crore in revenue, supported by a ₹117 crore total order book, though raw material cost pressures compressed standalone gross margins.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the Q2FY27 earnings conference call transcript detailing the group's turnaround to profitability and commencement of US commercial exports.
ஏன் இது முக்கியம்Innoxel's shift from development/milestone receipts into recurring US commercial contract manufacturing transforms group profitability and operating margins.
📅 குறுகிய காலம்Sentiment is likely to be supported by the group turning profitable after multiple loss-making quarters, alongside the commercialization milestone in the US.
📈 நீண்ட காலம்Structural transformation from domestic tender execution to higher-margin global CMO and biologics platforms could improve sustainable ROCE and cash flow generation.
⚠ அபாய எச்சரிக்கைகள்
Geopolitical input cost inflation compressing standalone gross margins (down to 35%) on fixed-price order books
Lumpiness in Innoxel's licensing and milestone revenues across quarters
👀 கவனிக்க வேண்டியவை
Track the ramp-up of US CMO manufacturing supplies through H2FY27 and monitor whether input cost headwinds continue to squeeze gross margins on the existing tender order book.
Q2 FY27 Consolidated Revenue jumps 111% YoY to ₹136.3 Cr; PAT swings to ₹11.8 Cr
Bharat Parenterals reported a turnaround in Q2 FY27 with consolidated revenue jumping 110.9% YoY to ₹136.3 Cr and net profit reaching ₹11.8 Cr (PAT to owners at ₹9.4 Cr), compared to a net loss of ₹8.6 Cr in Q2 FY26. Performance was primarily driven by 55.9%-owned subsidiary Innoxel Lifesciences, which swung to a ₹5.4 Cr PAT with revenue surging 253% YoY to ₹44.5 Cr following US commercial launch readiness. Additionally, the company completed a ₹139 Cr preferential issue on October 23, 2026, diluting equity by 11.7% to fund subsidiary investments, and upgraded Varenyam Bio's Phase 1 capex to ₹300 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுInnoxel Lifesciences achieved operational profitability with initial US commercial supplies, driving the consolidated group from multi-quarter losses back into net profit.
ஏன் இது முக்கியம்The company demonstrated operating leverage in high-margin injectables and CMO operations, while raising ₹139 Cr in equity to finance long-term biologics expansion.
Consolidated Q2 FY27 Revenue: ₹136.3 கோடிConsolidated Q2 FY27 PAT: ₹11.8 கோடிPreferential Fundraise: ₹139.0 கோடிFundraise vs Market Cap: ~8.9%Revised Varenyam Bio Capex: ₹300 கோடிStandalone Order Book: ₹184 கோடி
📅 குறுகிய காலம்Markets are likely to react positively to the strong operational turnaround and swing to profitability after consecutive quarters of consolidated net losses.
📈 நீண்ட காலம்Success hinges on sustained execution in US CMO contracts via Innoxel and the timely commissioning of the ₹300 Cr biologics facility without significant cost overruns.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of 11.7% from the recent ₹139 Cr preferential allotment
Execution risk on the large-scale ₹300 Cr biologics capex (near 75% of current net worth)
BPL standalone gross margins compressed to 34.8% due to higher COGS
👀 கவனிக்க வேண்டியவை
Track the commercial ramp-up of Innoxel's US CMO products and the execution progress of Varenyam Bio's revised ₹300 Cr Phase 1 capex targeted for Q2 2028.
Bharat Parenterals Q2 PAT Up 98.7% YoY to ₹5.4 Cr; Standalone Revenue Up 88.4%
Bharat Parenterals reported a 98.7% YoY surge in standalone profit after tax to ₹5.42 Cr for Q2 FY27, up from ₹2.73 Cr in Q2 FY26. Standalone revenue from operations grew 88.4% YoY to ₹78.55 Cr compared to ₹41.70 Cr in the year-ago period. Gross margins faced pressure due to raw material price inflation, dropping to 34.9% from 39.8% in Q1 FY27. Strong working capital discipline helped drive consolidated cash flow from operations to ₹83.33 Cr in H1 FY27, exceeding the ₹38.36 Cr achieved in the entire FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுBharat Parenterals posted strong Q2 standalone operational growth with revenue up 88.4% YoY and net profit nearly doubling, alongside strong working capital-driven cash generation.
ஏன் இது முக்கியம்Demonstrates robust demand execution and significant operating turnaround relative to previous loss-making quarters, although input cost pressures continue to weigh on gross margins.
Standalone Revenue (Q2): ₹7,855.44 லட்சம்Standalone Net Profit (Q2): ₹542.01 லட்சம்Order Book (as of 30 Sep 2026): ₹117.83 கோடிConsolidated H1 CFO: ₹83.33 கோடிPlanned Savli Capex: ₹300 கோடி
📅 குறுகிய காலம்Strong revenue acceleration and cash generation provide operational comfort, though input cost pressures on fixed-price order book may keep near-term margins sensitive.
📈 நீண்ட காலம்Diversification into hospital generics via Varenyam Healthcare and the ₹300 Cr oncology/biologics CDMO platform at Savli could significantly alter earnings scale if completed by Q2 FY28.
⚠ அபாய எச்சரிக்கைகள்
Gross margin compressed 490 bps QoQ due to geopolitical raw material inflation
Outstanding orders pre-priced before raw material inflation, exposing future margins to price volatility
👀 கவனிக்க வேண்டியவை
Track margin recovery against raw material input inflation and monitor execution timelines for the ₹300 Cr Savli expansion targeted for Q2 FY28.
Bharat Parenterals Limited has submitted revised EGM voting results held on October 23, 2026, to rectify an inadvertent classification error between institutional and non-institutional shareholders. The core resolutions, including the issuance of equity shares on a preferential basis and approval for investments/loans under Section 186 in excess of statutory limits, were approved unanimously with 100% of votes cast in favour (4,879,194 votes). Total votes polled represented 78.71% of outstanding shares across 3,757 recorded shareholders. The preferential issue terms, issue price, and amount details were not disclosed in this filing.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders formally approved the preferential equity issue and expanded borrowing/investment limits under Section 186, with reporting reclassified to properly categorize institutional voters.
ஏன் இது முக்கியம்Enables the company to execute planned equity capital raising and expand inter-corporate investments/loans, though capital dilution and fund size details remain to be seen.
Total votes cast in favour: 4,879,194Votes against: 0Total voting turnout: 78.7098%Total eligible shares: 6,198,963Total shareholders on record date: 3,757
📅 குறுகிய காலம்Administrative confirmation of shareholder approval; stock reaction will likely await final pricing and allotment terms.
📈 நீண்ட காலம்The capital raise could help repair the balance sheet following TTM losses of Rs -30 Cr, pending exact deployment details.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from preferential issue
Issue size and pricing not disclosed in the filing
👀 கவனிக்க வேண்டியவை
Watch for upcoming regulatory disclosures detailing the exact preferential issue size, pricing, allottees, and the formal allotment date.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Innoxel Lifesciences Commences First U.S. Commercial CMO Product Supply
Bharat Parenterals announced that its 55.9% subsidiary, Innoxel Lifesciences, commenced commercial supply to the United States on October 20, 2026. This marks Innoxel's first CMO product launch in the U.S. market, shifting its business model from purely one-off licensing income to recurring manufacturing revenues. In FY26, all ₹72.4 crore of Innoxel's revenue stemmed from licensing, whereas commercial batches will now add recurring volume-based revenue. Innoxel plans a second CMO launch in FY27 alongside further launches across FY28.
உச்சம் நம்பிக்கை
என்ன மாறியதுInnoxel transitioned from purely development and licensing revenue to recurring commercial finished-dosage supply in the U.S. market.
ஏன் இது முக்கியம்Adds recurring batch manufacturing revenue to Bharat Parenterals' consolidated top-line, potentially aiding margin recovery following TTM net losses of ₹30 crore.
📅 குறுகிய காலம்Positive sentiment driver as commercial dispatches to the U.S. validate regulatory compliance and CMO capabilities, setting up revenue growth in H2 FY27.
📈 நீண்ட காலம்Signals structural transformation into a regulated-market CDMO player, generating stable recurring revenue across 19 partners and potentially stabilizing group margins.
⚠ அபாய எச்சரிக்கைகள்
Product identity and commercial contract values are undisclosed due to confidentiality.
U.S. market volume uptake and sponsor marketing execution risk.
👀 கவனிக்க வேண்டியவை
Monitor upcoming quarterly results to track the ramp-up of recurring commercial CMO revenues and watch for the second planned U.S. commercial launch in FY27.
Bharat Parenterals to raise ₹139 Cr via preferential issue at ₹1,522.85/share; calls EGM on Oct 23
Bharat Parenterals has issued an EGM notice to approve a preferential equity issue of up to 9,12,759 shares at ₹1,522.85 per share, raising ₹138.99 Cr. The fundraise is targeted at marquee institutional investors including WhiteOak Capital funds, Aurum Rising India Fund, and Ashoka India Equity Investment Trust. The fundraise represents approximately 8.9% of the company's current market cap of ₹1,570 Cr and ~43% of TTM revenue. Following the allotment, promoter shareholding will dilute from 67.20% to 59.35%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has called an EGM on October 23, 2026, to approve a preferential share issuance raising ₹138.99 Cr from institutional investors and to expand Section 186 loan/investment limits.
ஏன் இது முக்கியம்The fundraise injects substantial equity (~35% of existing net worth of ₹402 Cr) into the balance sheet, helping offset recent operating losses and providing capital for business expansion.
Total Fundraise Amount: Rs. 138,99,95,043.15Issue Price per Share: Rs. 1522.85Shares to be Allotted: 9,12,759Fundraise vs Market Cap: ~8.9%Fundraise vs TTM Revenue: ~43.0%Post-issue Promoter Holding: 59.35%
📅 குறுகிய காலம்The issue price of ₹1,522.85 aligns closely with current trading prices (~₹1,517), which should provide near-term valuation support alongside institutional backing.
📈 நீண்ட காலம்Provides significant balance-sheet buffer and institutional validation after recent quarters of operational losses (TTM PAT of ₹-30 Cr).
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~11.7% of existing share capital (promoter stake drops from 67.20% to 59.35%)
Approval sought under Section 186 for loans/guarantees, requiring close watch on related-party or group exposures
👀 கவனிக்க வேண்டியவை
Track shareholder voting results at the EGM on October 23, 2026, and monitor subsequent disclosures regarding the specific end-use allocation of the ₹139 Cr proceeds.
Bharat Parenterals to raise ₹139 Cr via preferential allotment at ₹1522.85/share
Bharat Parenterals has approved a preferential allotment of up to 9,12,759 equity shares at ₹1522.85 per share to raise ₹138.99 crore. This fundraise represents ~8.9% of the current market capitalization and ~43% of TTM revenue (₹323 crore). The proceeds are earmarked for investments in or loans to subsidiaries for developing existing and new projects. Institutional investors, including several WhiteOak Capital entities, account for a substantial portion of the proposed allotment. An Extraordinary General Meeting (EGM) has been scheduled for October 23, 2026, to seek shareholder approval.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Board approved a preferential equity issue of ~₹139 crore to institutional and non-promoter investors, subject to shareholder approval.
ஏன் இது முக்கியம்The fundraise injects substantial capital (equivalent to ~43% of TTM revenue) into a currently loss-making company (TTM PAT of ₹-30 crore) to support subsidiary expansion without increasing leverage.
Total fundraise amount: Rs. 138,99,95,043.15Issue price per share: Rs. 1522.85Number of shares proposed: 9,12,759Fundraise vs TTM revenue: ~43.0%Fundraise vs Market cap: ~8.9%
📅 குறுகிய காலம்Shareholder approval at the October 23, 2026 EGM and regulatory clearances will be the immediate milestones to track.
📈 நீண்ட காலம்If successfully channeled into productive capacity or new formulations at the subsidiary level, this equity infusion could help reverse recent operating losses and strengthen balance sheet liquidity.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution for existing shareholders
Capital allocation risk if subsidiary projects fail to turn operational or profitable
👀 கவனிக்க வேண்டியவை
Monitor the voting outcome of the EGM on October 23, 2026, and look for subsequent disclosures detailing the specific subsidiary projects and timeline of capital deployment.
Bharat Parenterals' subsidiary, Varenyam Biolifesciences, has revised its Phase 1 capital expenditure for the Savli facility to ₹300 crore, doubling the previous estimate of ₹150 crore. The facility is being upgraded to include biologics and biosimilar CDMO capabilities alongside its existing oncology focus. This investment is highly material, representing approximately 87% of the company's TTM revenue and 93% of its net worth. The project targets high-regulated markets including the US and EU, with a targeted completion date of Q2 2028.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has doubled its investment and expanded the technical scope of its upcoming Savli facility to include high-value biologics CDMO services for regulated markets.
ஏன் இது முக்கியம்This represents a major strategic pivot from a Rest-of-World focus to high-barrier, regulated markets (US/EU), which could significantly improve revenue quality and margins if successfully executed.
Revised Phase 1 Capex: ₹300 கோடிCapex vs TTM Revenue: ~87%Capex vs Net Worth: ~93%Previous Capex Plan: ₹150 கோடிTarget Completion: Q2 2028
📅 குறுகிய காலம்The announcement is likely to be viewed positively by the market as a major growth signal, though the long gestation period means no immediate impact on earnings.
📈 நீண்ட காலம்If the facility achieves USFDA/EU-GMP approval by 2028, it could structurally transform the company's P&L by entering the high-margin biologics CDMO space.
⚠ அபாய எச்சரிக்கைகள்
Significant execution risk
Long gestation period (completion in 2028)
High capital intensity relative to current net worth
👀 கவனிக்க வேண்டியவை
Monitor the company's funding strategy for this ₹300 crore outlay given its current negative PAT and ROCE. Investors should track construction milestones and the eventual USFDA/EU-GMP inspection timeline toward 2028.
Bharat Parenterals reported a 19.2% YoY decline in consolidated revenue to ₹93.7 Cr for Q1 FY27, primarily due to a high base in the standalone business following the completion of a large ₹210 Cr institutional order. Despite the revenue drop, gross margins improved significantly by approximately 1,000 bps to 50.6% due to a better product mix. The company posted a consolidated net loss of ₹3.6 Cr, largely attributed to a ₹10.4 Cr loss at its Innoxel subsidiary, which is currently building capacity ahead of contracted revenue. Notably, subsidiaries Innoxel and Varenyam now contribute 46% of consolidated revenue, up from 21% a year ago.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is transitioning its revenue mix from standalone institutional tenders to subsidiary-led US/EU CDMO and domestic branded generics.
ஏன் இது முக்கியம்While the consolidated loss is a short-term headwind, the rapid growth of USFDA-compliant Innoxel and branded Varenyam suggests a structural shift toward higher-value pharmaceutical segments.
Consolidated Revenue (Q1): ₹93.7 கோடிRevenue vs TTM Revenue: 27.1%Gross Margin: 50.6%Innoxel Revenue Growth: 165% YoYConsolidated PAT: ₹(3.6) CrOwners Share of PAT: ₹1.0 கோடி
📅 குறுகிய காலம்The stock may face pressure due to the consolidated net loss and the 19% YoY revenue decline, despite management's explanation of the high base effect.
📈 நீண்ட காலம்The long-term outlook depends on Innoxel's ability to leverage its USFDA EIR for high-margin US commercial supply and Varenyam's scaling in the domestic branded market.
⚠ அபாய எச்சரிக்கைகள்
Continued losses at Innoxel subsidiary
High operating expenses (41.5% of revenue)
Execution risk in highly regulated US/EU markets
👀 கவனிக்க வேண்டியவை
Monitor the EBITDA break-even timeline for the Innoxel subsidiary and the sustainability of the 50%+ gross margins as the business shifts from low-margin tenders to branded and CDMO sales.
Bharat Parenterals Q1 Results: Revenue Drops 19% YoY to ₹93.74 Cr, Returns to Profitability
Bharat Parenterals reported a consolidated revenue of ₹93.74 cr for Q1 FY27, marking a 19.2% decline from ₹116.00 cr in the same quarter last year. Despite the revenue drop, the company returned to a standalone net profit of ₹3.66 cr, a significant sequential improvement from the ₹8.16 cr loss in the preceding March quarter, though down 63.4% YoY. Consolidated EBITDA margins (excluding other income) contracted to 9.10% from 11.88% YoY. The board also approved the re-appointment of Mr. Hemang Shah as Executive Director for a five-year term.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a loss-making trend in the previous three quarters to a profitable Q1 FY27, although it faces significant YoY top-line and margin pressure.
ஏன் இது முக்கியம்For a company with a high Price-to-Book ratio of 10.3 and a TTM loss of ₹27 cr, the sharp decline in revenue suggests growth challenges, even as cost controls helped achieve a quarterly profit.
Consolidated Revenue (Q1 FY27): ₹93.74 கோடிYoY Revenue Growth: -19.2%Standalone Net Profit (Q1 FY27): ₹3.66 கோடிConsolidated EBITDA Margin: 9.10%Q1 வருவாய் vs TTM வருவாய்: 27.1%
📅 குறுகிய காலம்The stock may face pressure due to the significant YoY decline in revenue and profit, despite the sequential turnaround from losses.
📈 நீண்ட காலம்The company needs to demonstrate consistent revenue growth and margin stabilization to justify its current valuation; the current contraction is a structural concern.
⚠ அபாய எச்சரிக்கைகள்
Significant YoY revenue contraction
Margin compression
High valuation (P/B 10.3) relative to recent loss-making history
👀 கவனிக்க வேண்டியவை
Investors should monitor if the company can sustain this return to profitability after a loss-making FY26, and watch for management commentary regarding the sharp 19% YoY revenue contraction.
Bharat Parenterals Q1 FY27: Standalone Net Profit at ₹3.66 Cr, Revenue Declines 19% YoY
Bharat Parenterals reported a consolidated revenue of ₹93.74 Cr for Q1 FY27, representing a 19.2% decline from ₹116.00 Cr in the same quarter last year. On a standalone basis, the company achieved a net profit of ₹3.66 Cr, a notable recovery from the ₹8.16 Cr loss reported in the preceding March 2026 quarter. Consolidated EBITDA margins (including other income) contracted to 10.29% from 12.79% YoY. The board also approved the re-appointment of Mr. Hemang Shah as Executive Director for a five-year term.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company transitioned from a loss-making quarter in March 2026 to a profitable one in June 2026 on a standalone basis, despite a year-on-year revenue contraction.
ஏன் இது முக்கியம்After reporting a net loss of ₹27 Cr in FY26, returning to profitability is a critical step for the company to improve its negative ROCE (-2.0%) and justify its high P/B valuation of 10.3.
Consolidated Revenue (Q1 FY27): ₹93.74 கோடிStandalone Net Profit (Q1 FY27): ₹3.66 கோடிConsolidated EBITDA Margin: 10.29%Revenue vs TTM Revenue: ~27.2%Standalone Finance Costs: ₹0.69 கோடி
📅 குறுகிய காலம்The return to standalone profitability may provide some support to the stock price, though the significant YoY revenue decline remains a concern.
📈 நீண்ட காலம்The company needs to demonstrate consistent revenue growth and margin expansion to recover from its recent annual losses and high debt-to-equity ratio of 0.45.
⚠ அபாய எச்சரிக்கைகள்
Significant YoY revenue decline of 19.2%
High P/B ratio of 10.3 relative to recent loss-making history
Negative ROCE of -2.0%
👀 கவனிக்க வேண்டியவை
Monitor the company's ability to sustain standalone profitability and reverse the YoY revenue decline in upcoming quarters. Watch for management commentary during the AGM on September 19 regarding the strategy to improve consolidated margins.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
